Pharmaceuticals
10 pharmacovigilance experts
These ten professionals have led pharmacovigilance and drug safety work inside their own companies, with titles such as Head of Pharmacovigilance Operations and Systems and Vice President, Head of Pharmacovigilance. A reader can learn how companies organize and run pharmacovigilance.
Professionals to explore
01—10Alexander Kluczka
LinkedInExperience: Head of Pharmacovigilance Operations and Systems · Bristol Myers Squibb
Head of Pharmacovigilance Operations and Systems at Bristol Myers Squibb since March 2024. Former Global Pharmacovigilance, Head TA Oncology - ICSR Processing at Bayer (2012–2024) and Global Pharmacovigilance - TA Head Specialized Therapeutics - Risk Management at Bayer (2007–2010). Also former Pharmacovigilance Country Head and UK QPPV at Schering Health Care Limited (2004–2007).
Ankur Makadia
LinkedInExperience: Head of International Pharmacovigilance Operations & Americas · UCB
Former Head of International Pharmacovigilance Operations & Americas at UCB (2022–2025), a role the profile describes as providing strategic leadership and oversight to International Pharmacovigilance Operations, QPPV Operations and PV for the Americas region. Head of Pharmacovigilance Quality at UCB since September 2024. Other listed UCB roles include Head of Safety Data Insights (2018–2022).
Barbara Del Carlo
LinkedInExperience: Head of Global Pharmacovigilance Operations, Deputy EU UK QPPV · Chiesi Group
Former Head of Global Pharmacovigilance Operations, Deputy EU UK QPPV at Chiesi Group (2015–2022) and EU QPPV at Kedrion Biopharma (2006–2011). Glabal Regional Head, Deputy EU UK QPPV at argenx since December 2022, where the profile lists ensuring compliance with local, regional and global safety regulatory requirements and providing strategic PV support in the regions.
Deepa Venkataraman
LinkedInExperience: Vice President, Head of Global Patient Safety and Pharmacovigilance · Corcept Therapeutics
Vice President, Head of Global Patient Safety and Pharmacovigilance at Corcept Therapeutics since June 2022. Former SVP, Head of Global Patient Safety, Pharmacovigilance and Quality Assurance at Summit Therapeutics, Inc. (2021–2022) and Head of Global Case Management, Medical Coding and Medical Safety Review, PPS at AbbVie (2020–2021). The profile cites over 20 years of experience.
Donna Valencia
LinkedInExperience: Vice President, Head of Pharmacovigilance · Adverum Biotechnologies
Vice President, Head of Pharmacovigilance at Adverum Biotechnologies since March 2025 and Executive Director, Head of Pharmacovigilance there from 2024 to 2025. Former Vice President, Head of Drug Safety at Immune-Onc Therapeutics (2022–2024) and Vice President and Senior Director, Head of Patient Safety and Epidemiology at Sio Gene Therapies (2017–2022).
Laura Lindsey
LinkedInExperience: Vice President & Global Head, Pharmacovigilance & Risk Management · Keenova
Vice President & Global Head, Pharmacovigilance & Risk Management at Keenova since January 2016. Former Head, Global Pharmacovigilance Operations, Compliance & Training at GE HealthCare (2012–2016) and Associate Director, Drug Safety at Celgene Corporation (1998–2001). The profile cites experience across case processing and aggregate reporting.
Lilliam Fernandes
LinkedInExperience: Head of Global Pharmacovigilance · US WorldMeds
Head of Global Pharmacovigilance at US WorldMeds since June 2026 and Director for Clinical Safety and Pharmacovigilance there from 2025 to 2026. Former Director for Clinical Safety and Pharmacovigilance (2016–2025) and Associate Director For Clinical Safety and Pharmacovigilance (2012–2016) at Adaptimmune. The profile cites over 23 years of experience across biotech start-ups and global pharmaceutical organizations.
Mandeep Singh
LinkedInExperience: VP, Global Head of Pharmacovigilance and Drug Safety · Ascendis Pharma
VP, Global Head of Pharmacovigilance and Drug Safety at Ascendis Pharma since June 2021 and Senior Director, Pharmacovigilance Safety Evaluation there from 2020 to 2021. Former Director, Head PV Clinical Group, US Drug Safety (2018–2020) and Director, Head of Case Management (2016–2018) at Genentech.
Priya Nandi
LinkedInExperience: Executive Director, Drug Safety & Pharmacovigilance · Coherus Oncology
Executive Director, Drug Safety & Pharmacovigilance at Coherus Oncology since July 2023. Former Director Pharmacovigilance (2018–2023) and Associate Director, Pharmacovigilance (2015–2018) at Clovis Oncology, and Assistant Director, US Pharmacovigilance Medical Records Team at Bayer (2012–2014). The profile describes a Pharmacovigilance Leader proficient in setting up a global PV system and building PV teams.
Sepideh Habibi, MD
LinkedInExperience: VP, Head of Safety and Pharmacovigilance · Eledon Pharmaceuticals, Inc.
VP, Head of Safety and Pharmacovigilance at Eledon Pharmaceuticals, Inc. since February 2025, a role the profile describes as overseeing PV operation, PV compliance and medical safety, including PV governance. Former Global Head of Pharmacovigilance and Risk Management at CRISPR Therapeutics (2020–2025), Head of Pharmacovigilance at REGENXBIO (2019–2020) and Vice President, Global Head of Drug Safety and Pharmacovigilance at Sucampo Pharmaceuticals, Inc. (2011–2018).
Choose the right perspective
Match the person's seat to your question, since a head of safety at a small biotech often builds the whole function while a leader at a large company usually owns one part of it, such as case processing or quality. Also ask whether the person has worked on marketed products, trial-stage products or both, because reporting duties and inspection exposure differ.
Questions to take into the conversation
- 01What should a small drug company build in-house for pharmacovigilance and what can it safely outsource?
- 02How do you set up signal detection so real safety issues surface early without drowning the team in noise?
- 03What do regulators look at most closely during a pharmacovigilance inspection, and how do you prepare?
Reaching pharmacovigilance experts
How can I contact one of these pharmacovigilance experts?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 10 companies, including Bristol Myers Squibb, UCB and Chiesi Group, based on profile data retrieved on October 3, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach pharmacovigilance experts?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal